Breast cancer study pulled before it began: new combo never tested

This study was designed to test whether adding the experimental drug boserolimab to standard chemotherapy and immunotherapy before surgery could help people with high-risk, early-stage triple-negative breast cancer. The goal was to see if the combination was safe and could eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. However, the study was withdrawn before enrolling any participants, so no results are available.